CN114875037B - Chicken GBP4L gene, expression vector and application - Google Patents
Chicken GBP4L gene, expression vector and application Download PDFInfo
- Publication number
- CN114875037B CN114875037B CN202210612622.4A CN202210612622A CN114875037B CN 114875037 B CN114875037 B CN 114875037B CN 202210612622 A CN202210612622 A CN 202210612622A CN 114875037 B CN114875037 B CN 114875037B
- Authority
- CN
- China
- Prior art keywords
- chicken
- gbp4l
- gene
- heat stress
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 88
- 239000013604 expression vector Substances 0.000 title claims abstract description 17
- 101001058844 Homo sapiens Guanylate-binding protein 7 Proteins 0.000 title abstract description 64
- 230000008642 heat stress Effects 0.000 claims abstract description 67
- 230000014509 gene expression Effects 0.000 claims abstract description 11
- 238000009395 breeding Methods 0.000 claims abstract description 8
- 230000001488 breeding effect Effects 0.000 claims abstract description 8
- 239000002773 nucleotide Substances 0.000 claims abstract description 7
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 7
- 241000700605 Viruses Species 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 abstract description 21
- 238000001727 in vivo Methods 0.000 abstract description 5
- 230000035882 stress Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 230000001276 controlling effect Effects 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 235000013330 chicken meat Nutrition 0.000 description 68
- 210000000952 spleen Anatomy 0.000 description 27
- 102100028533 Guanylate-binding protein 7 Human genes 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 11
- 241000702421 Dependoparvovirus Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 102000003914 Cholinesterases Human genes 0.000 description 9
- 108090000322 Cholinesterases Proteins 0.000 description 9
- 229940048961 cholinesterase Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 8
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 244000144977 poultry Species 0.000 description 8
- 235000013594 poultry meat Nutrition 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 210000001669 bursa of fabricius Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 102000006395 Globulins Human genes 0.000 description 5
- 108010044091 Globulins Proteins 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000004727 humoral immunity Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241001260012 Bursa Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 3
- 229960004359 iodixanol Drugs 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- -1 IL-1β Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000012214 genetic breeding Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150094765 70 gene Proteins 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 101100447470 Gallus gallus GAPDH gene Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/30—Bird
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the technical field of genetic engineering, and particularly relates to a chicken GBP4L gene, an expression vector and application. The nucleotide sequence of the chicken GBP4L gene is shown as SEQ ID NO: 1. The invention proves that the GBP4L gene is related to chicken heat stress for the first time, and can effectively relieve the phenotypes of inflammatory factor increase, immune organ injury and the like caused by chicken heat stress by regulating and controlling the in vivo high expression of the GBP4L gene. The research result of the invention has good application prospect in the aspects of relieving chicken heat stress and breeding heat-resistant stress chicken varieties.
Description
Technical Field
The invention belongs to the technical field of genetic engineering, and particularly relates to a chicken GBP4L gene, an expression vector and application.
Background
The heat stress seriously affects the development of animal husbandry, causes great loss to the global breeding industry every year, and the current mainstream livestock and poultry variety cannot effectively dissipate heat due to the lack of sweat glands on the skin surface, is sensitive to the change of the environmental temperature, and the heat stress caused by the overhigh temperature brings adverse effects to the production of livestock and poultry. Under the state of heat stress, the electrolyte balance, the glycolipid metabolism, the antioxidant system and the intestinal health of the organism are negatively affected, so that the livestock and poultry have low emotion, inappetence and reduced organism immunity.
How to relieve heat stress of broiler chickens is a problem which puzzles the breeding industry, and the traditional ways of relieving heat stress such as increasing the daily ration energy concentration or applying additives such as electrolyte, mineral substances, vitamins and Chinese herbal medicine preparations have some limiting factors in application, functions and the like. The research on chicken heat stress related genes is hopeful to fundamentally solve chicken heat stress reaction and improve the economic benefit of poultry cultivation.
The Chinese patent application with publication number of CN101948832A discloses a heat resistance related molecular marker on a heat stress protein 70 gene, which is obviously related to the heat resistance property of chickens, and aims to cultivate chickens of heat-resistant strains through a genetic breeding method. Genetic breeding by using auxiliary molecular markers is one of ways for solving chicken heat stress reaction, and genes related to chicken heat stress are discovered, so that the action mechanism of chicken heat stress reaction can be further and fundamentally researched, and the effectiveness and pertinence for relieving chicken heat stress are improved.
Disclosure of Invention
The invention aims to provide a chicken GBP4L gene, which proves that the GBP4L gene is related to chicken heat stress for the first time.
The second object of the present invention is to provide an expression vector comprising the above-mentioned chicken GBP4L gene.
A third object of the present invention is to provide adeno-associated recombinant viruses produced from the above expression vectors.
The fourth object of the invention is to provide the application of the chicken GBP4L gene, the expression vector and the adeno-associated recombinant virus.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
a chicken GBP4L gene has a nucleotide sequence shown in SEQ ID NO: 1.
The invention proves that the GBP4L gene is related to chicken heat stress for the first time, and can effectively relieve the phenotypes of inflammatory factor increase, immune organ injury and the like caused by chicken heat stress by regulating and controlling the in vivo high expression of the GBP4L gene. The research result of the invention has good application prospect in the aspects of relieving chicken heat stress and breeding heat-resistant stress chicken varieties.
An expression vector containing the chicken GBP4L gene.
The expression vector can be used for constructing corresponding transformant, thereby effectively relieving chicken heat stress.
Preferably, the starting vector of the expression vector is an adeno-associated viral vector.
Adeno-associated recombinant viruses produced using the expression vectors described above.
The gland related recombinant virus technology is used, the safety is good, the technology is mature, and the chicken heat stress can be effectively relieved.
The chicken GBP4L gene, the expression vector and the adeno-associated recombinant virus are applied to relieving chicken heat stress.
Preferably, the GBP4L gene is highly expressed, so that the heat stress of the chicken is relieved.
Preferably, the chicken is a fixed-start chicken.
The application of the chicken GBP4L gene in the breeding of heat stress resistant chicken varieties.
Preferably, the chicken is a fixed-start chicken.
Drawings
FIG. 1 shows the nucleotide sequence and corresponding amino acid sequence of chicken GBP4L gene;
FIG. 2 is a prior art tool carrier map;
FIG. 3 is a final vector map of the present invention;
FIG. 4 shows the positive cloning sequence in the present invention;
FIG. 5 is a graph showing AAV viral packaging results according to the present invention; wherein, (a) AAV virus packaging process (200×); (B) Real-time PCR detection results, 293T-PMT602 is a control plasmid PMT602 transfected 293T cell sample, 293T-PSE5343 is a target plasmid PSE5343 transfected 293T cell sample;
FIG. 6 shows the in vivo expression results of recombinant GBP4L adeno-associated viruses of the invention;
FIG. 7 shows the effect of GBP4L on heat stressed chicken immune-related factors according to the invention;
FIG. 8 shows the effect of GBP4L on spleen tissue structure of heat stressed chicken according to the present invention.
Detailed Description
The invention will now be described in more detail with reference to the drawings and examples. The experimental materials involved in the following examples are illustrated below:
test animals: the fixed-start chickens are from the original yang germplasm resource field of Henan agricultural university.
The test reagents are shown in table 1 below:
TABLE 1 test Main reagent
The main instruments are shown in table 2 below:
table 2 main instrument for test
Example 1 Chicken GBP4L Gene
The nucleotide sequence of the chicken GBP4L gene of the embodiment is shown as SEQ ID NO:1, the nucleotide sequence and the corresponding amino acid sequence of the chicken GBP4L gene are shown in figure 1.
Example 2 expression vectors containing the chicken GBP4L Gene
The expression vector containing the chicken GBP4L gene of this example was obtained by ligating the chicken GBP4L gene with an adeno-associated virus vector (AAV). The carrier patterns of the tool carrier and the final carrier used in this example are shown in fig. 2 and 3, respectively.
The GBP4L sequence is synthesized by Shanghai and constructed on the target vector. Screening positive clone and sequencing and verifying, wherein the sequencing result of the positive clone is shown in figure 4 (SEQ ID NO: 2), which shows that pAAV-GBP4L-3FLAG adeno-associated virus recombinant plasmid is successfully constructed.
1. Recombinant AAV virus-out and packaging
The HEK293 cell line was used to produce adeno-associated recombinant viruses, and HEK293 cells were cell lines obtained by transforming human embryonic kidney cells with sheared adenovirus type 5 DNA, which produced virus particles with infectious capacity when the cells were co-transformed with AAV Helper-Free System three plasmids (including plasmids of interest, pAAV-RC and pHelper).
AAV virus-out and packaging steps:
(1) 24h before transfection, spread 2X 10 in 15cm Petri dishes 7 HEK293 cells were cultured in DMEM medium containing 10% FBS, 37℃and 5% CO 2 Culturing in an incubator for 24 hours;
(2) The cell density on the day of transfection reached 70-80%, pHelper plasmid, pCap/rap plasmid and destination plasmid were added in a ratio of 6:5:3 to a 5ml EP tube and mixed well, 500uL serum free DMEM was added and labeled A;
(3) 110uL of 1 XPI transfection reagent was added to another 1.5ml EP tube and the total volume was made up to 500uL with serum free DMEM medium, labeled B (note: the medium was seen to turn orange in color);
(4) Slowly adding the transfection reagent in the B tube into the A tube, and incubating for 5min at room temperature;
(5) In the incubation process, HEK293 cells for packaging AAV are subjected to liquid exchange, and each dish is exchanged into a serum-free DMEM culture medium;
(6) After incubation, the mixture in tube A was added to the cells evenly, the cells were placed in 37℃with 5% CO after gentle shaking of the dish 2 Culturing in an incubator for 4-8 hours;
(7) The culture medium is changed into a complete culture medium, and the culture is continued for 72 hours, and then the virus collection is prepared.
2. Recombinant pAAV-GBP4L-3FLAG virus purification
The recombinant pAAV-GBP4L-3FLAG virus was purified as follows:
(1) Collecting supernatant in a cell culture dish in a 50mL centrifuge tube, and centrifuging at 4000rpm for 10min;
(2) The supernatant was discarded and the pellet was resuspended by adding 3mL of 1 XPBS per tube;
(3) Blowing off cells in a culture dish by using 5-10 mL PBS, loading the cells into another 50mL centrifuge tube, and centrifuging at 4000rpm for 5-10min;
(4) The PBS was discarded, and 5mL of 1 XPBS was added to each tube to resuspend the pellet;
(5) Placing all the 50mL centrifuge tubes with the resuspended cells into a liquid nitrogen tank, freezing for 10-15min, taking out, placing into a water bath kettle at 37 ℃ for thawing, and repeatedly freezing and thawing for 4 times;
(6) The lysed cells were centrifuged at 4000rpm for 5min and the supernatant was collected in a new centrifuge tube and added to treat the nuclease, notes: after being cracked by a physical method, the centrifuged cells are not easy to adhere to the wall, the whole cells are stuck together to form a jelly state, the operation step needs caution, and the cracked cells are difficult to remove on the side;
(7) About 7-8mL of supernatant was loaded into a new 15mL centrifuge tube;
(8) Preparing discontinuous iodixanol gradie, sequentially adding 17% layer,25% layer, 40% layer and 60% layer of iodixanol into a centrifuge tube, and adding AAV supernatant solution into the uppermost layer of each tube discontinuous iodixanol gradient;
(9) Balancing a centrifuge tube, and centrifuging at 40,000rpm for 2.5 hours;
(10) Carefully remove the centrifuge tube and collect the band of interest.
The virus concentration steps are as follows:
(1) Preparing an ultrafiltration tube, adding 5mL of 1 XPBS to infiltrate a filter membrane, and centrifuging at 4000rpm for 5min;
(2) The collected viruses were diluted ten times with 1 XPBS and filtered into ultrafiltration tubes with a 0.22um filter head;
(3) Centrifuging the ultrafiltration tube at 4000rpm for 10-20min;
(4) Repeating the steps 2 and 3, and finally concentrating the virus liquid to 0.8mL;
(5) Sucking the concentrated AAV virus into a 1.5mL EP tube, adding glycerol, and the final concentration of glycerol is 10%;
(6) Viruses were split and 10uL removed for titer detection.
3. Recombinant pAAV-GBP4L-3FLAG virus titer assay
Currently, the titer of AAV is determined by quantitative PCR detection of the genomic copy number of AAV vectors to determine the number of viral particles of AAV. The procedure for determining the titer of the recombinant pAAV-GBP4L-3FLAG virus is as follows: standard pAAV Standard plasmid 10 3 ,10 4 ,10 5 ,10 6 ,10 7 Diluting the detection sample 1000 and 10000 times, wherein the reaction system is shown in table 3, and the reaction conditions are as follows: denaturation at 95 ℃ for 10min,40 cycles: 95℃for 10s and 60℃for 35s.
TABLE 3Real-time PCR reaction System
In Table 3, WPREs-F: TTACGCTATGTGGATACG;
WPREs-R:GCAAGAACTAACCAGGAT。
as shown in FIG. 5A, the target plasmid PSE5343 is transfected into a 293T cell sample, the obvious Expression of Green Fluorescent Protein (EGFP) is observed under a fluorescence inversion microscope after transfection, and the Real-time PCR detection result shows (FIG. 5B) that the GBP4L gene is obviously over-expressed, which indicates that the construction of the GBP4L gene over-expression plasmid is successful.
The results of adeno-associated virus titer measurements are shown in Table 4.
TABLE 4 adeno-associated Virus titre results
The result of the titer test shows that the pAAV-GBP4L-3FLAG titer is 5.43 * 10 11 vg/mL。
Example 3 application of alleviating Heat stress in chickens and Breeding of chickens
3.1 animal test design and sample preparation
48 healthy fixed-start cock with similar weight for 28 days are selected as study objects, placed in isolated clean chicken houses, and fed in a cage raising mode, and the illumination, temperature and humidity are strictly controlled in the feeding process. The animals were randomly divided into A, B, C, D groups of 12 chickens. Wherein, group A is a control group, group B is a heat stress group, group C is a heat stress+control AAV group (without insertion of GBP4L recombinant fragment AAV, pAAV-3 FLAG), group D is a heat stress+over-expression GBP4L recombinant AAV group (insertion of GBP4L recombinant fragment AAV, pAAV-GBP4L-3 FLAG). Group C administration of cervical subcutaneous purified pAAV-3FLAG virus with a viral load of 2.43 * 10 10 vg; group D administration neck subcutaneous purified pAAV-GBP4L-3FLAG virus with a viral load of 2.43 * 10 10 vg. The control group A is fed at normal temperature, the temperature is controlled at 21+/-1 ℃, the heat stress group B, C, D is fed at 32+/-1 ℃, and the treatment is continued for 4 weeks, namely 28 days.
Slaughter experiments were performed at trial 29 d. Fasted measures are taken 12 hours before slaughtering, and water is normally drunk. Weighing the hollow living body, performing neck exsanguination and sacrifice after diethyl ether anesthesia, collecting blood, placing in a coagulation promoting tube, standing at room temperature for 30min, centrifuging at 3500r/min for 15min, separating serum, and freezing and preserving at-20 ℃. Spleen and bursa tissue were dissected and isolated, the organ surface was blotted dry with filter paper, weighed and data recorded. Immune organs were snap frozen in liquid nitrogen and transferred to-80℃for storage.
3.2 determination of the expression level of GBP4L Gene in spleen tissue
Four A, B, C, D groups of 5 biological replicates were randomly selected and total chicken spleen tissue RNA was extracted separately using the RNAiso Plus kit. The expression level of GBP4L gene in spleen tissue is detected by adopting a qRT-PCR method. The GBP4L gene primer sequence is as follows:
F:5’-ACGCCTGGATCTTCACACTG-3’;
R:5’-CAGTCCTCGGCCTCATCTTC-3’。
the qRT-PCR method is as follows: by reverse transcription of the cDNA obtained, using96 fluorescent quantitative PCR instrumentThe PremixEx TaqTM kit was used for qRT-PCR. The reaction system is shown in Table 5.
TABLE 5 qRT-PCR reaction System
qRT-PCR amplification procedure was as follows: the extension was performed at 95℃for 3min,95℃for 30s,60℃for 30s,72℃for 30s, and 72℃for 10min for 35 cycles. Taking chicken GAPDH gene as an internal reference and adopting 2 -ΔΔCt The relative expression level of the gene was calculated by the method. Three biological and three technical replicates were set up for each reaction.
3.3 immune related index detection
Detection of IgG, igM, CD3 in serum by enzyme-linked immunosorbent assay (ELISA) kit + 、CD4 + Corticosterone, TNF-alpha, IL-1 beta, IL-6, TGF-beta, NF-kB cytokine concentrations. The specific procedures were strictly followed by the instructions for ELISA kit use. The specific operation is as follows:
(1) Sample adding of standard substance: setting a standard substance hole and a sample hole, wherein 50 mu L of standard substances with different concentrations are respectively added into the standard substance hole;
(2) Sample adding: blank holes (blank control holes are not added with samples and enzyme-labeled reagents, and the rest steps are the same) and sample holes to be tested are respectively arranged. And adding 40 mu L of sample diluent into the sample hole to be detected on the enzyme-labeled coated plate, and then adding 10 mu L of sample to be detected. Adding a sample at the bottom of an ELISA plate hole, slightly shaking and uniformly mixing without touching the hole wall as much as possible;
(3) Adding enzyme: adding 100 mu L of enzyme-labeled reagent into each hole, except for blank holes;
(4) Incubation: sealing with sealing plate membrane, and incubating at 37deg.C for 60min;
(5) Preparing liquid: diluting 20 times of concentrated washing liquid with distilled water for later use;
(6) Washing: carefully removing the sealing plate film, discarding the liquid, spin-drying, filling the washing liquid in each hole, standing for 30s, discarding, repeating the operation for 5 times, and beating to dry;
(7) Color development: 50 mu L of the color-developing agent A and 50 mu L of the color-developing agent B are added into each hole, and the mixture is gently vibrated and mixed uniformly, and developed for 15min at 37 ℃ in a dark place;
(8) And (3) terminating: add 50. Mu.L of stop solution per well to stop the reaction (blue turning yellow immediately at this time);
(9) And (3) measuring: the absorbance (OD value) of each well was measured sequentially at a wavelength of 450nm in blank Kong Diaoling. The measurement should be performed within 15min after the addition of the stop solution.
3.4, blood Biochemical index detection
The blood Glucose (GLU), triglyceride (TG), total Cholesterol (TC), glutamic pyruvic transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), cholinesterase (CHE), total Protein (TP), globulin (GLB), albumin (ALB), albedo, lactate Dehydrogenase (LDH) levels were measured using a fully automated biochemical analyzer.
3.5 immune organ index determination
The spleen and bursa immune organ indexes of 12 chickens in each group are measured, and the immune organ indexes are calculated according to the formula:
immune organ index (%) = immune organ weight (g)/chicken live weight (g) ×100%.
3.6 preparation of Paraffin tissue sections
And 5 spleen tissues of chickens are randomly collected in A, B, C, D groups, fixed for more than 24 hours through a 4% formaldehyde solution, then washed and dehydrated for 12 hours, paraffin embedded and sliced, spread and pasted, dewaxed, hematoxylin-eosin dyed, washed and differentiated, rinsed and dehydrated, counterstained, dehydrated and transparent, and finally sealed and then sliced. Histological observations of the sections were performed with a system biological microscope.
3.7 statistical analysis
Statistical analysis was performed using SPASS 20.0 software, experimental data were expressed as mean ± standard deviation, single factor analysis of variance and independent sample t-test were used for statistical analysis, P <0.05 was considered statistically significant, P <0.01 was considered extremely significant, and Graphpad Prism 5 was used for graphical drawing.
3.8, results and analysis
3.8.1 recombinant GBP4L adeno-associated virus in vivo expression results
As shown in FIG. 6, the viral load was 2.43 * 10 10 The heat stress model chicken injected with vg recombinant GBP4L adeno-associated virus is detected by adopting a qRT-PCR method, and the result shows that the expression level of GBP4L gene in spleen tissue of the chicken is obviously higher than that in a control group (P < 0.05), the GBP4L gene in the heat stress group injected with pAAV-GBP4L-3FLAG vector is obviously higher than that in the control group (P < 0.05), and the GBP4L gene is up-regulated by 7 times, thus indicating that the recombinant GBP4L adeno-associated virus is successfully injected in vivo, and the spleen tissue can obviously express the GBP4L gene in a high degree.
3.8.2 Effect of GBP4L on Heat stress chicken immune-related factors
As shown in FIG. 7, CD3 in serum was detected using ELISA kit + 、CD4 + IgG, igM, corticosterone, TNF-alpha, IL-1 beta, IL-6, TGF-beta, NF-kB cytokine concentrations, results show that heat stress group serum CD3 + 、CD4 + IgG and IgM levels were significantly lower than those of the control group (P < 0.05), and corticosterone and TNF-alpha, IL-1β, IL-6, TGF- β, and NF-kB cytokine concentrations were significantly higher than those of the control group (P < 0.05). CD3 + And CD4 + The T cells, the reactive cell immunity level, the IgG and IgM reactive humoral immunity level and the blood corticosterone level can be used as reliable indexes of the poultry in a stress state, so that the heat stress model is successfully constructed.
Serum CD3 of heat stress + control AAV group + 、CD4 + IgG, igM, corticosterone, TNF-alpha, IL-1 beta, IL-6, TGF-beta, NF-kB cytokine concentrations were not significantly different from the heat stress group (P > 0.05). Heat stress + overexpression of GBP4L recombinant AAV-group serum CD3 + IgG levels significantly higher than in the heat stress group (P < 0.05), CD4 + IgM levels were higher than in the heat stressed group (P > 0.05) and were not significantly different from the control group (P > 0.05); the heat stress + the recombinant AAV group with GBP4L over-expressed serum corticosterone and TNF-alpha, IL-1 beta, IL-6, TGF-beta, NF-kB cytokine concentration is significantly lower than that of the heat stress group (P < 0.05), and the corticosterone and TNF-alpha, IL-6, TGF-beta, NF-kB cytokine concentration is not significantly different from that of the control group (P > 0.05).
From the above results, it was found that injection of recombinant adeno-associated virus GBP4L gene can effectively alleviate chicken serum CD3 caused by thermal stress + 、CD4 + The levels of IgG and IgM are reduced, the concentration of corticosterone and TNF-alpha, IL-1 beta, IL-6, TGF-beta and NF-kB cytokines is increased, the inflammatory reaction caused by heat stress is relieved, and the immune state of the organism is improved.
3.8.3 and GBP4L effects on the Biochemical index of blood of Heat stressed chickens
The results of measuring Glucose (GLU), triglyceride (TG), total Cholesterol (TC), glutamic pyruvic transaminase (ALT), aspartic transaminase (AST), alkaline phosphatase (ALP), cholinesterase (CHE), total Protein (TP), globulin (GLB), albumin (ALB), white ball ratio, lactate Dehydrogenase (LDH) levels in blood using a full-automatic biochemical analyzer are shown in table 6.
TABLE 6 influence of GBP4L on the biochemical index of blood of heat stressed chickens
Note that: different letters represent P <0.05, and the same letters represent P > 0.05.
The results in table 6 show that none of the four GLB, ALB, white ball ratio, TP, LDH differences are significant (P > 0.05) for the control group a, the heat stress group B, the heat stress + the control AAV group C, the heat stress + the GBP4L overexpressing recombinant AAV group D; the heat stress group B GLU, ALT, AST, TC level is significantly higher than the control group a (P < 0.05), the CHE, ALP, TG level is significantly lower than the control group a (P < 0.05), the heat stress + GBP4L recombinant AAV group D group CHE, GLU, AST, TC level is significantly lower than the heat stress group B (P < 0.05), the ALT level is lower than the heat stress group B (P > 0.05), the CHE, ALP, TG level is significantly higher than the heat stress group B (P < 0.05), and the CHE, TG, GLU, ALT, AST, ALP, TC level is not significantly different from the control group a (P < 0.05).
From the above results, it can be seen that injection of recombinant adeno-associated virus GBP4L gene can effectively relieve heat stress by increasing GLU, ALT, AST, TC level and decreasing CHE, ALP, TG level of chicken serum.
3.8.4 Effect of GBP4L on Heat stress chicken immune organ index
Spleen is the largest peripheral immune organ of poultry, participates in cellular immunity and humoral immunity of organisms, and bursa of fabricius is the peculiar central immune organ of poultry, which dominates the humoral immunity of organisms. The weight of immune organ can be used to evaluate the immune status of chicken, the greater the relative weight and absolute weight, the stronger the cellular immunity and humoral immunity of the organism. Immune organ index is an important index reflecting the immune function of poultry. Four spleen and bursa organ indices of control group A, heat stress group B, heat stress+control AAV group C, heat stress+over-expressed GBP4L recombinant AAV group D were examined and the results are shown in Table 7.
TABLE 7 Effect of GBP4L on heat stressed chicken immune organ index
The results show that the indexes of spleen and bursa of Fabricius organs of the heat stress group B are lower than those of the control group A (P is more than 0.05), the indexes of spleen and bursa of Fabricius organs of the heat stress + over-expressed GBP4L recombinant AAV group D are higher than those of the heat stress group B (P is more than 0.05), and the indexes of spleen and bursa of Fabricius organs of the four groups are not obvious (P is more than 0.05).
From the results, the spleen and bursa of Fabricius immune organ indexes of the chicken are reduced due to heat stress, and the pAAV-GBP4L-3FLAG vector is injected to improve the spleen and bursa of Fabricius immune organ indexes of the heat-stressed chicken and relieve the heat stress.
3.8.5 Effect of GBP4L on spleen tissue Structure of Heat stressed chickens
To understand the effect of GBP4L on the spleen tissue structure of heat stressed chickens, four groups A, B, C, D were randomly collected in this study, 5 chicken spleen tissues each were fixed with 4% formaldehyde solution for more than 24h, and paraffin tissue sections were prepared. Histological observations of the sections were performed using a system biological microscope, and the results are shown in fig. 8.
The result shows that the spleen tissue envelope structure of the control group A is clear, red and white marrow is mixed and distributed, the white marrow is dispersed and penetrates through the whole spleen and mainly contains small lymphocytes, sheath arteries and a small quantity of lymph nodes, and the red marrow comprises venous sinuses and reticular spleen sinuses containing reticulocytes, macrophages, lymphocytes and erythrocytes, and no obvious abnormality is seen; the spleen tissue of the heat stress group B can see a small amount of lymphocyte necrosis, and the nuclei shrink or disintegrate (black arrow), and other obvious abnormalities are not seen; the heat stress + control AAV group C tissue can see a large number of lymphocyte necrosis, shrinkage or fragmentation of cell nuclei (black arrow), and the interstitial mass can see more eosinophilic homogeneous mass (red arrow), and other obvious abnormalities are not seen; the heat stress and over-expression GBP4L recombinant AAV group D tissue envelope has clear structure, red and white marrow is mixed and distributed, the white marrow is dispersed and penetrated in the whole spleen, and mainly contains small lymphocytes, sheath arteries and a small amount of lymphatic nodules, and the red marrow comprises venous sinuses and reticular spleen sinuses containing reticulocytes, macrophages, lymphocytes and erythrocytes, and no obvious abnormality is seen.
From the results, the spleen tissue structure of the chicken is damaged due to heat stress, lymphocyte necrosis is caused, and the spleen tissue damage caused by the heat stress can be alleviated by injecting pAAV-GBP4L-3FLAG vector.
Based on the experimental results, individuals with high expression GBP4L genes can be bred, and then the heat-resistant stress chicken variety is bred by utilizing a general breeding technology.
<110> Henan agricultural university
<120> chicken GBP4L gene, expression vector and application
<160> 6
<170> PatentIn version 3.5
<210> 1
<211> 1881
<212> DNA
<213> Gallus gallus
<221> chicken GBP4L Gene
<400> 1
atggacgctc cggtgctccc gatgccggct ccgctctgcc tggtgaccaa caaggacggc 60
gtgctcgccc tcaaccccgc agcgctggca gtgctgcagg aggtggccca gcctatggtg 120
gtggtggcca tcgctgggcc ctaccgcacc gggaagtcct tcctgatgaa ccggctggca 180
cagaagcgca ctggcttccc gctgggcccc acggtgcagg cagagaccaa gggcatctgg 240
atgtggtgcc tgcagcaccc acgccagcag ggagtgacct tgatgctgct ggacactgag 300
ggcctgggag accccaaaaa gggtgacagc cacaatgacg cctggatctt cacactggcg 360
ctgctgttgt ccagcaccct ggtgtacaac agcataggca ccatcgacca gaaggcactg 420
gagaacctcg agctggtgac acagctgtcg gagctgatcc gggtgcggga cagggacaag 480
gacggcaaca acagcgttga aagagaagat gaggccgagg actgcgagtt cgtgcgctac 540
ttccccagct ttgtgtgggt ggtgagggac ttcacgctgg agctgcgcgt gggcgagcgg 600
cccatcagtg aggatgagta cctggagcag gtgctggaac tcaagcacgg gcatggccgc 660
aaggtgcaga actacaatgg gacgcggctc tgcctccgca actatttccc cacacggaag 720
tgcttcgtgc tgcctccgcc actgggcaca gaggagtgcg ggcgcatgga ggagctgccc 780
gaggctgcac tggccccacg tttcctccaa caggcagccc agttctgcaa ctacgtgctg 840
agctccacca ggctcaagac gctgcctgac ggcagagcac tgacagggcg agccctgtgc 900
atgctgctgc agagctacgt ggaggccatc aacagcgggc atctgccctg cctggaggga 960
gcagcggcag tgatgatggc caacgagaat gcagcggcgg tggcggcagc gctggaggcc 1020
tataccaggg gcatgcgggg gctgtcactg cccacagagc ctgcacagct ctcggccgcg 1080
catggggagc acctgcatga ggcactcatt gtcttccagc gtcgcagctt ccgggatcgt 1140
gaccaggagc accagcggcg cctcatggaa cagatcagca cagagtacag ccacctgcag 1200
gaggagaatg atgaagcatc acggcagcac tgcaaggcac tgctggctga gctggcacag 1260
gcactgcata ccagcctggc ccgtggggcc tacacacagc ccggaggcta ccgcgcctac 1320
gaggccgagc ggcagcggct gctggagggc tatcggcaag cggagggcaa gggccccaag 1380
gccgaggagg tgctgaatga gttcctggcg gagcgtcggg cagaggcaga ggcagtgctg 1440
aaggcagaca atgcactgag cgaggccgag aagcagctgg aggaccagaa gcagcaggcg 1500
cagctcctgg agcagcggca gaaagcgacg gcggagcgcg aacggcagct ggaggcgctg 1560
ctagaggacg agcgcaacag ctacgcgcag aacctgcaag ccctggaggc caagatgcag 1620
gcggaggcgg agagcgcgca gcgggagctg cagcgggcga tggaagcgaa gctacgggag 1680
cagagagagc tgctgcagcg cggcttcaga gagcaggcgg cgctgatgga gcaggagctg 1740
gcggcgctgc ggcgggagag caacaacaac agcaagcagg agctggcggc ctccattttc 1800
gacaccgtgc gcgccgcctg cgacctcgtc agcacgttaa aactgtccaa gctggccaag 1860
tcacggggaa cagcagtgta g 1881
<210> 2
<211> 2874
<212> DNA
<213> artificial sequence
<220>
<221> vector sequence
<222> (1)...(75)
<220>
<221> cleavage site
<222> (76)...(81)
<220>
<221> GBP4L sequence
<222> (88)...(1965)
<220>
<221> 3flag sequence
<222> (1966)...(2037)
<220>
<221> P2A-EGFP sequence
<222> (2047)...(2838)
<220>
<221> cleavage site
<222> (2839)...(2844)
<220>
<221> vector sequence
<222> (2845)...(2874)
<400> 2
ccgtcagatc gcctggagac gccatccacg ctgttttgac ctccatagaa gacaccggga 60
ccgatccagc ctccgggatc cgccaccatg gacgctccgg tgctcccgat gccggctccg 120
ctctgcctgg tgaccaacaa ggacggcgtg ctcgccctca accccgcagc gctggcagtg 180
ctgcaggagg tggcccagcc tatggtggtg gtggccatcg ctgggcccta ccgcaccggg 240
aagtccttcc tgatgaaccg gctggcacag aagcgcactg gcttcccgct gggccccacg 300
gtgcaggcag agaccaaggg catctggatg tggtgcctgc agcacccacg ccagcaggga 360
gtgaccttga tgctgctgga cactgagggc ctgggagacc ccaaaaaggg tgacagccac 420
aatgacgcct ggatcttcac actggcgctg ctgttgtcca gcaccctggt gtacaacagc 480
ataggcacca tcgaccagaa ggcactggag aacctcgagc tggtgacaca gctgtcggag 540
ctgatccggg tgcgggacag ggacaaggac ggcaacaaca gcgttgaaag agaagatgag 600
gccgaggact gcgagttcgt gcgctacttc cccagctttg tgtgggtggt gagggacttc 660
acgctggagc tgcgcgtggg cgagcggccc atcagtgagg atgagtacct ggagcaggtg 720
ctggaactca agcacgggca tggccgcaag gtgcagaact acaatgggac gcggctctgc 780
ctccgcaact atttccccac acggaagtgc ttcgtgctgc ctccgccact gggcacagag 840
gagtgcgggc gcatggagga gctgcccgag gctgcactgg ccccacgttt cctccaacag 900
gcagcccagt tctgcaacta cgtgctgagc tccaccaggc tcaagacgct gcctgacggc 960
agagcactga cagggcgagc cctgtgcatg ctgctgcaga gctacgtgga ggccatcaac 1020
agcgggcatc tgccctgcct ggagggagca gcggcagtga tgatggccaa cgagaatgca 1080
gcggcggtgg cggcagcgct ggaggcctat accaggggca tgcgggggct gtcactgccc 1140
acagagcctg cacagctctc ggccgcgcat ggggagcacc tgcatgaggc actcattgtc 1200
ttccagcgtc gcagcttccg ggatcgtgac caggagcacc agcggcgcct catggaacag 1260
atcagcacag agtacagcca cctgcaggag gagaatgatg aagcatcacg gcagcactgc 1320
aaggcactgc tggctgagct ggcacaggca ctgcatacca gcctggcccg tggggcctac 1380
acacagcccg gaggctaccg cgcctacgag gccgagcggc agcggctgct ggagggctat 1440
cggcaagcgg agggcaaggg ccccaaggcc gaggaggtgc tgaatgagtt cctggcggag 1500
cgtcgggcag aggcagaggc agtgctgaag gcagacaatg cactgagcga ggccgagaag 1560
cagctggagg accagaagca gcaggcgcag ctcctggagc agcggcagaa agcgacggcg 1620
gagcgcgaac ggcagctgga ggcgctgcta gaggacgagc gcaacagcta cgcgcagaac 1680
ctgcaagccc tggaggccaa gatgcaggcg gaggcggaga gcgcgcagcg ggagctgcag 1740
cgggcgatgg aagcgaagct acgggagcag agagagctgc tgcagcgcgg cttcagagag 1800
caggcggcgc tgatggagca ggagctggcg gcgctgcggc gggagagcaa caacaacagc 1860
aagcaggagc tggcggcctc cattttcgac accgtgcgcg ccgcctgcga cctcgtcagc 1920
acgttaaaac tgtccaagct ggccaagtca cggggaacag cagtggacta caaggatgac 1980
gatgacaagg attacaaaga cgacgatgat aaggactata aggatgatga cgacaaaact 2040
agttccggaa gcggagctac taacttcagc ctgctgaagc aggctggaga cgtggaggag 2100
aaccctggac cttccggaat ggtgagcaag ggcgaggagc tgttcaccgg ggtggtgccc 2160
atcctggtcg agctggacgg cgacgtaaac ggccacaagt tcagcgtgtc cggcgagggc 2220
gagggcgatg ccacctacgg caagctgacc ctgaagttca tctgcaccac cggcaagctg 2280
cccgtgccct ggcccaccct cgtgaccacc ctgacctacg gcgtgcagtg cttcagccgc 2340
taccccgacc acatgaagca gcacgacttc ttcaagtccg ccatgcccga aggctacgtc 2400
caggagcgca ccatcttctt caaggacgac ggcaactaca agacccgcgc cgaggtgaag 2460
ttcgagggcg acaccctggt gaaccgcatc gagctgaagg gcatcgactt caaggaggac 2520
ggcaacatcc tggggcacaa gctggagtac aactacaaca gccacaacgt ctatatcatg 2580
gccgacaagc agaagaacgg catcaaggtg aacttcaaga tccgccacaa catcgaggac 2640
ggcagcgtgc agctcgccga ccactaccag cagaacaccc ccatcggcga cggccccgtg 2700
ctgctgcccg acaaccacta cctgagcacc cagtccgccc tgagcaaaga ccccaacgag 2760
aagcgcgatc acatggtcct gctggagttc gtgaccgccg ccgggatcac tctcggcatg 2820
gacgagctgt acaagtaaaa gcttatcgat aatcaacctc tggattacaa aatt 2874
<210> 3
<211> 18
<212> DNA
<213> artificial sequence
<221> WPREs-F
<400> 3
<210> 4
<211> 18
<212> DNA
<213> artificial sequence
<221> WPREs-R
<400> 4
gcaagaacta accaggat 18
<210> 5
<211> 20
<212> DNA
<213> artificial sequence
<221> F
<400> 5
<210> 6
<211> 20
<212> DNA
<221> R
<213> artificial sequence
<400> 6
cagtcctcgg cctcatcttc 20
Claims (6)
1. Chicken (chicken)GBP4LGene, comprising said chickenGBP4LGene expression vector comprising the sameGBP4LApplication of gene adeno-associated recombinant virus in preparation of chicken heat stress relieving products, characterized in thatGBP4LThe nucleotide sequence of the gene is shown in SEQ ID NO: 1.
2. The use according to claim 1, wherein the starting vector of the expression vector is an adeno-associated viral vector.
3. The use according to claim 1, wherein the expression is highGBP4LThe gene can relieve chicken heat stress.
4. The use according to any one of claims 1 to 3, wherein the chicken is a fixed-start chicken.
5. Chicken (chicken)GBP4LApplication of gene in breeding heat stress resistant chicken varietyCharacterized in that the chickenGBP4LThe nucleotide sequence of the gene is shown in SEQ ID NO: 1.
6. The use according to claim 5, wherein the chicken is a fixed-start chicken.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210612622.4A CN114875037B (en) | 2022-05-31 | 2022-05-31 | Chicken GBP4L gene, expression vector and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210612622.4A CN114875037B (en) | 2022-05-31 | 2022-05-31 | Chicken GBP4L gene, expression vector and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114875037A CN114875037A (en) | 2022-08-09 |
CN114875037B true CN114875037B (en) | 2023-06-06 |
Family
ID=82680250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210612622.4A Active CN114875037B (en) | 2022-05-31 | 2022-05-31 | Chicken GBP4L gene, expression vector and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114875037B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101629178A (en) * | 2009-08-06 | 2010-01-20 | 中国农业科学院哈尔滨兽医研究所 | Manually-combined Newcastle diseases virus F gene and recombining expression vector and application thereof |
CN101948832A (en) * | 2010-09-16 | 2011-01-19 | 华南农业大学 | Heat resistance associated molecular marker on chicken heat stress protein 70 gene and acquiring method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2136209A4 (en) * | 2007-03-05 | 2010-10-27 | Eisai R&D Man Co Ltd | Method for examination of action of anti-cancer agent utilizing splicing defect as measure |
-
2022
- 2022-05-31 CN CN202210612622.4A patent/CN114875037B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101629178A (en) * | 2009-08-06 | 2010-01-20 | 中国农业科学院哈尔滨兽医研究所 | Manually-combined Newcastle diseases virus F gene and recombining expression vector and application thereof |
CN101948832A (en) * | 2010-09-16 | 2011-01-19 | 华南农业大学 | Heat resistance associated molecular marker on chicken heat stress protein 70 gene and acquiring method and application thereof |
Non-Patent Citations (3)
Title |
---|
"PREDICTED: Gallus gallus guanylate-binding protein 4-like (GBP4L), mRNA",Accession Number:XM_015292901 .1;genbank;《GenBank》;第1-2页 * |
"TMT-based quantitative proteomic analysis reveals the spleen regulatory network of dexamethasone-induced immune suppression in chicks";Yujie Guo et al.;《Journal of Proteomics》;第248卷;第1-9页 * |
"家禽应激性免疫抑制研究新策略";翟敏茜 等;《》;第39卷(第3期);第74-79页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114875037A (en) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103930542A (en) | Brown fat cell compositions and methods | |
CN114174520A (en) | Compositions and methods for selective gene regulation | |
CN110241071A (en) | A kind of normal renal tubule primary cell of people and its Isolation and culture and application | |
CN114807142A (en) | Circular RNA-circ-Magi1 and application thereof | |
CN113088522B (en) | Japanese eel transcription factor c-Rel gene promoter and application thereof | |
CN114875037B (en) | Chicken GBP4L gene, expression vector and application | |
CN113633775A (en) | Application of agent for over-expressing phosphofructokinase in preparation of drugs for delaying cell senescence | |
CN108774633A (en) | It is a kind of for Cerebral Infarction Treatment simultaneously can be by the neural stem cell preparation of magnetic resonance and fluorescence imaging bimodal tracer | |
CN113005095A (en) | Method for regulating ovarian granulosa cells based on circ-Atp5BP | |
Comer et al. | Detection of mRNA species in bulbospinal neurons isolated from the rostral ventrolateral medulla using single-cell RT–PCR | |
CN115607689A (en) | Application of KLF7 gene in preparation of drug for reversing cell senescence | |
CN111575384B (en) | Application of human GLT8D1 gene in clinical diagnosis and treatment of tumor | |
CN110628818B (en) | Preparation method and application of fish skin mucous gland bioreactor | |
CN109939222B (en) | Medical application of CREG protein for promoting skeletal muscle regeneration | |
CN109563512A (en) | For treating the truncation Dysferlin of Dysferlin myopathy | |
CN113604474A (en) | Application of GPx8 as molecular target in preparation of anti-aging drugs | |
CN117327703B (en) | Agrin-shRNA of targeted smooth muscle cells and application of Agrin-shRNA in preparation of anti-atherosclerosis drugs | |
CN112574943A (en) | Model for simulating dermatophyte infection in vitro and establishing method and application thereof | |
CN112094854A (en) | Specific primer, probe and kit for detecting pelodiscus sinensis flavivirus | |
CN117603973B (en) | ShRNA of targeted inhibition Agrin gene and application thereof | |
CN111849981B (en) | sgRNA based on PLIN1 gene, plasmid vector, construction method and application thereof | |
CN117205225B (en) | Application of geniposide in preparation of medicament for treating myeloproliferative neoplasm | |
CN114231494B (en) | Application and method of USP10 gene and/or Ascl1 gene in inducing fibroblast to transdifferentiate into neuron cell | |
CN116855503B (en) | Stable transgenic cell strain over-expressing MRGPRX2 and construction method and application thereof | |
CN113599523B (en) | Application of GPx8 as molecular target in preparation of medicine for preventing and/or treating fatty liver |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |